GW PHARMACEUTICALS, A DRUG COMPANY THAT SPECIALIZES IN CANNABIS-BASED PHARMACEUTICALS, HAS RECEIVED EARLY APPROVAL ON A PATENT COVERING THE USE OF MARIJUANA CHEMICALS FOR TREATING BRAIN CANCER.
GW Pharmaceuticals introduced Wednesday that it’s been issued a Notice of Allowance from the U.S. Patent Office for a patent utility regarding the use of THCand CBD, the two principal chemical substances in marijuana, for treating gliomas.
Once a patent application is deemed a actual invention, the Patent Office sends a Notice of Allowance that outlines the prices involved with final approval.Specifically, the agency provides this description of the patent:
“The situation patent in particular covers a technique for treating glioma in a human using a combination of cannabidiol (CBD) and tetrahydrocannabinol (THC) in which the cannabinoids are in a ratio of from 1:1 to at least one:20 (THC:CBD) with the reason to lessen cellular viability, inhibit mobile growth or reduce tumor quantity.”
Filed in 2009, GW’s patent software lists Otsuka Pharmaceutical as a collaborator and first of all claimed the discovery of the “use of a mixture of cannabinoids in the manufacture of a medicament for use in the remedy of most cancers.”